Media Advisory For Federal Appeals Court – Psilocybin Case Hearing

Media Advisory For Federal Appeals Court – Psilocybin Case Hearing

Link to oral arguments: https://youtu.be/39MhxZ8SQ0U

Article about the hearing: https://www.marijuanamoment.net/federal-court-hears-case-challenging-dea-decision-to-deny-psilocybin-rescheduling-petition-without-consulting-health-officials/?fbclid=IwAR139IISoWU1peXCNr04xgkM3N9rgCk9OybBMI3-hxkY7AAABbyGD373YnA

An interview I gave on awake.net: https://awake.net/aims-vs-dea-right-to-try-psilocybin-for-end-of-life-court-hearing-of-deas-denial-on-petition-to-reschedule-psilocybin-friday-oct-20-2023-9-am-phoenix-azhttps-youtu-be-ud1vsa69e6msitufvgxoy/

Media Advisory

  • Right to Try and psychedelics subject matter experts are available for interviews or quotes about the Ninth Circuit Court of Appeals case, Aggarwal v. Drug Enforcement Agency (DEA).
  • The case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin (commonly called magic mushrooms) from a highly restricted Schedule I drug to a less restricted Schedule II so that it can be accessed by physicians and other providers to help those with terminal and other life-threatening conditions.
  • This case focuses on DEA’s long history of applying an inaccurate test to rescheduling petitions. The outcome of this case could have implications for other emerging and promising therapies.
  • A live stream of the argument will be available October 20, 2023 at 9:00 a.m. MST at https://www.ca9.uscourts.gov/media/live-oral-arguments/

Available for Comment

kathryn@yournpa.org

  • Matthew C. Zorn, YETTER COLEMAN LLP, 713.632.8064, mzorn@yettercoleman.com

(counsel presenting argument)

spennington@porterwright.com

Additional Background

On Friday, October 20, 2023, at 9:00 AM MST in Phoenix, Arizona, the Ninth Circuit Court of Appeals will hear arguments in Aggarwal v Drug Enforcement Agency (DEA) (No. 22-1718; AIMS III).

The case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin from a highly restricted Schedule I drug to a less restricted Schedule II category.

Dr. Sunil Aggarwal, a Seattle palliative care physician and co-founder of the Advanced Integrative Medical Science Institute (AIMS), and several of his patients with advanced cancer sought access to psilocybin, an investigational drug shown to offer remarkable relief from anxiety and depression in terminally ill patients.

As a Schedule I drug, Psilocybin can only be accessed with the DEA’s permission. Initially, Dr. Aggarwal sought permission under state and federal Right to Try (RTT) laws, which legislatures enacted to facilitate access to promising investigational drugs to patients with life-threatening conditions.

During a lawsuit related to RTT (AIMS I), the DEA suggested that Dr. Aggarwal file a rescheduling petition. He did so, filing a nine-page petition. DEA denied the Petition with four sentences.

The Court will consider whether the DEA’s denial was unlawful and may order the DEA to refer the petition to Health and Human Services (FDA) for further medical and scientific evaluation.

About the National Psychedelics Foundation

The NPA Foundation is a registered 501(c)(3) non-profit organization dedicated to educating and supporting those providing Psychedelic Assisted Care. Our mission is to guide providers through the opportunities, risks, and legal complexities inherent in the field. We focus on three core pillars: Accessibility, Affordability, and Availability.

We engage in various activities and programs to achieve our mission, including legal and regulatory guidance, financial empowerment and support, and community engagement. We collaborate with research institutions, policymakers, and the community to advocate for evidence-based policies and practices in Psychedelic Assisted Care.

For more information visit yournpa.org 10-18-23 press release

Leave a Reply

Latest Blog Posts

Proactive Breast Health: Self-Care and Self-Exam Tips for Breast Cancer Prevention

Proactive Breast Health: Self-Care and Self-Exam Tips for Breast Cancer Prevention

by Clinical Consulting Team This post was written by our guest author, Raushanah Najeeullah, ND. Breast cancer affects approximately one in eight women, making it one of the most common cancers worldwide. While genetic factors can influence breast cancer risk, lifestyle choices and early detection play an important role in prevention. Nutrient and hormone influences, and possibly estrogen metabolism, might be contributors to breast cancer development. Select use of testing and addressing results, could influence optimal breast health and may be associated with reducing breast cancer risk. The DUTCH Test (Dried Urine Test for Comprehensive Hormones) provides potential valuable insights ...

Read More
New Urine Test Reduces Unnecessary Biopsies in Prostate Cancer Detection

New Urine Test Reduces Unnecessary Biopsies in Prostate Cancer Detection

Author: Raushanah Najeeullah, ND A new urine test, MyProstateScore 2.0 (MPS2), offers better accuracy for detecting high-grade prostate cancer compared to current methods. In a recent study involving over 1,500 men, MPS2 reduced unnecessary biopsies by up to 51% while still identifying significant cancers with high sensitivity. This test improves on the PSA test by specifically targeting 17 genes linked to high grade aggressive prostate cancer, making it a promising non-invasive tool for reducing the risks and discomfort associated with prostate cancer screening. Source: Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test ...

Read More
Brain cancer update

Brain cancer update

July 12, 2024 Leanna Standish IV CURCUMIN AIMS Institute’s integrative oncology team is investigating the therapeutic effects of intravenous curcumin in treating the most aggressive type of brain cancer, called glioblastoma.  Curcumin is the molecule present in turmeric root that has anticancer activity.  Curcumin has been shown in cell culture experiments to cause the programmed death of glioblastoma cells.  We use IV curcumin in order to provide sufficient levels of curcumin to the brain that will slow tumor growth.  Our brain cancer patients are enrolled in AIMS Institute’s IRB-approved study called the AIMS CANCER OUTCOMES STUDY.  Last year we presented ...

Read More
Call Us Text Us
Skip to content